

**PROGRAM GRANT AGREEMENT  
BETWEEN  
THE GLOBAL FUND TO FIGHT AIDS, TUBERCULOSIS AND MALARIA  
("Global Fund")  
AND THE UNITED NATIONS DEVELOPMENT PROGRAMME  
("Principal Recipient")**

1. Country: Sao Tome and Principe		
2. Program Title: Strengthening the HIV/AIDS epidemic response among vulnerable groups and Most-at-risk population in Sao Tome and Principe		
3. Grant Number: STP-011-G05-H		3A. Modification Number and Date: Not applicable
4. Program Starting Date: 1 January 2012	5. Program Ending Date: 31 December 2013	6. Proposal Completion Date: 31 December 2016
6A. Condition Precedent Terminal Date: 1 September 2012	6B. Condition Precedent Terminal Date: N/A	6C. Condition Precedent Terminal Date: N/A
7. Grant Funds: Up to the amount of US\$ 1,081,582 (One Million, Eighty One Thousand, Five Hundred and Eighty Two United States Dollars).		
8. Program Coverage:   X HIV/AIDS   ___ Tuberculosis   ___ Malaria   ___ HIV/AIDS/Tuberculosis		
9. Information for Principal Recipient Bank Account into Which Grant Funds Will Be Disbursed:		
10. The fiscal year of the Principal Recipient is from 1 January to 31 December.		
11. LFA Swiss Tropical and Public Health Institute Address Socinstrasse 57, 4002 Basel Tel. +41 61 284 81 38 Fax +41 61 284 81 03 Attention: Charlotte Kristiansson E-mail: charlotte.kristiansson@unibas.ch		
12. Principal Recipient Additional Representative:  Antonio de Lima Viegas Assistant Resident Representative United Nations Development Programme BP 109 Sao Tome, Sao Tome & Principe Tel.: +239 22 11 22/23 Fax: +239 22 21 98 E-mail: Antonio.viegas@undp.org		13. Global Fund Additional Representative:  Dr Cyrille Dubois Regional Team Leader, West Africa Chemin de Blandonnet 8 1214 Vernier-Geneva, Switzerland  Tel.: +41 58 791 1700      Fax: +41 58 791 1701
14. This Agreement consists of the two pages of this face sheet and the following: Standard Terms and Conditions      Annex A – Program Implementation Abstract		

15. Signed for the Principal Recipient by its Authorized Representative	Date <u>15/12/2011</u>
Mr Antonio <u>[REDACTED]</u> UNDP Assistant Resident <u>[REDACTED]</u>	
16. Signed for the Global Fund by its Authorized Representative	Date <u>15/12/11</u>
Prof. Michèl Kazatchkin <u>[REDACTED]</u> ✓ Executive Director	
17. Acknowledged by the Chair of the Country Coordinating Mechanism	Date <u>14/12/2011</u>
Mrs. Angela Dos Santos Ramos Jose da Costa Pinheiro Minister of Health Ministry of Health of Sao Tome and Principe	
18. Acknowledged by Civil Society Representative of the Country Coordinating Mechanism	Date <u>15/12/2011</u>
Mr. Manuel <u>[REDACTED]</u> Carvalho do Rio President Federation of non-Governmental Organizations, Sao Tome and Principe	
19. Entry into Force: This Agreement, prepared in two originals, shall enter into force on the date of its signature by both the Principal Recipient and the Global Fund, acting through their duly Authorized Representatives identified in blocks 15 and 16 above.	

## ANNEX A to the PROGRAM GRANT AGREEMENT

### Program Implementation Abstract

<b>Country:</b>	<b>Sao Tome and Principe</b>
<b>Program Title:</b>	<b>Strengthening the HIV/AIDS epidemic response among vulnerable groups and Most-at-risk population in Sao Tome and Principe</b>
<b>Grant Number:</b>	<b>STP-011-G05-H</b>
<b>Disease:</b>	<b>HIV/AIDS</b>
<b>Principal Recipient:</b>	<b>United Nations Development Programme (UNDP)</b>

#### **A. PROGRAM DESCRIPTION**

##### **1. Background and Summary:**

Sao Tome and Principe is Africa's smallest economy. The per capita income of US\$424 places the country below the average for Sub-Saharan Africa. Approximately 54 percent of its population of 163,874 is poor and 15 percent live in extreme poverty. The country ranks 131 out of 182 countries in the 2009 UNDP Human Development Index. Life expectancy is 67 years and the adult literacy rate is estimated at 83%.

The first AIDS case in Sao Tome and Principe was reported in 1990 and since then, 390 cases have been identified by the Ministry of Health through the country's health districts. The majority of cases are associated to sexual transmission, mostly heterosexual.

The HIV epidemic in Sao Tome and Principe shows characteristics of both generalized and concentrated epidemics. According to the Demographic Health Survey (DHS) conducted in 2008/2009, the prevalence of HIV infection in the general population aged 19-49 years old is 1.5%, which corresponds to a pattern of generalized epidemics. However, the prevalence among men (1.7%) is higher than among women (1.3%), which characterize concentration of cases in high-risk groups. These findings are reinforced by the data from sentinel surveillance that points out a low prevalence (0.6%) among pregnant women and a high prevalence among sex workers (4.2%).

The epidemiologic data from the autonomous region of Principe indicate that the epidemic in this region is spreading faster than in Sao Tome, with a prevalence of 2.2%.

This program will address the following HIV/AIDS issues in Sao Tome and Principe, among others: voluntary testing and counseling; prevention activities for targeted populations, including sex workers and their clients and men who have sex with men (MSM); integration of prevention of mother-to-child transmission (PMTCT) services at the health district level; and treatment for opportunistic infections.

2. **Goal:**

To decrease the morbidity and mortality of HIV infection among people living with HIV/AIDS in Sao Tome and Principe.

3. **Target Group/Beneficiaries:**

- Sex Workers
- MSM
- Pregnant women
- Orphans and Vulnerable Children
- Patients co-infected with TB
- General Population

4. **Strategies:**

- Mass media communication for behavior change through interventions directed to the general population
- Peer education and other prevention interventions targeting most-at-risk populations: sex workers and their clients, MSM, patients with Sexually Transmissible Infections (STIs) and people living with HIV/AIDS (PLWHA).
- Expansion of voluntary testing and counseling for HIV.
- Integration of PMTCT activities in all reproductive health and prenatal care services, at every Health District.
- Diagnosis and treatment of STIs, through syndromic approach management, at all health centers and clinics, free of charge.

5. **Planned Activities:**

- Increase HIV testing in all health centers throughout the islands
- Promote good health care including STI treatment and HIV testing and safer sex amongst sex workers and their clients and MSM
- Have educative activities including promotion of human rights and stigma reduction
- Strengthen STI treatment for patients and their partners
- Secure second-line ARV treatment for adults and children
- Provide state of the art prophylaxis and treatment for HIV patients co-infected with TB
- Deliver outreach and social support interventions to HIV infected pregnant women on issues related to preventing mother-to-child transmission, safe infant feeding, (including the correct preparation of infant formula and administration of cotrimoxazole for the infant, among others)
- Train health care workers on risk of occupational exposure and blood safety measures
- Provide support services to Orphans and Vulnerable Children

## **B. CONDITIONS PRECEDENT TO DISBURSEMENT**

### **1. Conditions Precedent to Second Disbursement (Terminal Date as stated in block 6A of the Face Sheet)**

The second disbursement of Grant Funds by the Global Fund to the Principal Recipient is subject to the delivery by the Principal Recipient to the Global Fund of the following, each in form and substance satisfactory to the Global Fund:

- a. The final report on the Monitoring and Evaluation Systems Strengthening Tool (the “MESS Tool”) implemented by the Principal Recipient, in consultation with the Program stakeholders, from 7 to 11 June 2011 (the “MESS Tool Report”);
- b. An updated plan for monitoring and evaluating program activities (the “Updated M&E Plan”), which shall, without limitation:
  - i. Incorporate the recommendations made by the Global Fund Secretariat and program stakeholders upon completion of the MESS Tool; and
  - ii. Include a budgeted action plan for the implementation of the monitoring and evaluation system strengthening interventions identified in the MESS Tool Report;
- c. An updated Performance Framework which incorporates updated baselines and targets for impact and outcome indicators in alignment with the revised HIV/AIDS National Strategy for the years 2012-2016;
- d. A revised budget for the period beginning with the Program Starting Date and ending with the Program Ending Date (the “Revised Program Budget”) which incorporates:
  - i. The interventions identified in the MESS Tool Report; and
  - ii. Any amendments to the budget approved by the Global Fund as of the effective date of this Agreement necessitated by the Updated M&E Plan and/or the updated Performance Framework; and
- e. The written approval of the Global Fund of each of the Updated M&E Plan, the updated Performance Framework, and the Revised Program Budget.

### **2. Conditions Precedent to Disbursement of Grant funds for Training Activities**

The use by the Principal Recipient of Grant funds for the financing of training activities under the Program is subject to the satisfaction of each of the following conditions:

- a. The delivery by the Principal Recipient to the Global Fund of a detailed training plan and budget which is in form and substance satisfactory to the Global Fund and which covers all trainings that the Principal Recipient proposes to conduct (the “Detailed Training Plan and Budget”); and
- b. The written approval by the Global Fund of the Detailed Training Plan and Budget.

### **3. Conditions Precedent to Disbursement of Grant funds for Consulting Activities**

The use by the Principal Recipient of Grant funds for the financing of activities to be conducted by consultants for the positions/roles under the Program of “Reviewing the M&E Framework”; “Conducting Capacity-Building on HIV Prevention for Sex Workers”; “Capacity-Building and Execution of HIV Prevention for MSM”; “Follow-Up of HIV Positive Patients”; and “Update of ARV and IO Management Guidelines” is subject to the satisfaction of each of the following conditions:

- a. The delivery by the Principal Recipient to the Global Fund of a detailed consultancy plan and budget which is in form and substance satisfactory to the Global Fund and which includes, without limitation, the terms of reference for each consultancy position (the “Consultancy Plan and Budget”) and;
- c. The written approval by the Global Fund of the Consultancy Plan and Budget.

### **C. SPECIAL TERMS AND CONDITIONS FOR THIS AGREEMENT**

1. The parties acknowledge that as of the date of the signature of this Agreement, the Global Fund has not approved the plan for the procurement, use and supply management of Health Products (the “PSM Plan”) consistent with Article 18 of the Standard Terms and Conditions of this Agreement. Consistent with such Standard Terms and Conditions, the disbursement by the Global Fund or use by the Principal Recipient of Grant funds for the procurement of Health Products is conditional upon the approval by the Global Fund of the PSM Plan.

2. The parties agree that the requirement in Article 14 of the Standard Terms and Conditions of this Agreement that the Principal Recipient provide, not later than 90 days after this Agreement enters into force, a plan for monitoring the Program, is replaced with the condition for second disbursement in Section B.2 above.

3. The Principal Recipient acknowledges and agrees that the Global Fund has entered into this Agreement with the Principal Recipient in reliance on the representation by the Country Coordinating Mechanism that the funds provided under this Agreement do not constitute more than 65% of the funds for the national HIV/AIDS program in Sao Tome and Principe. If the Principal Recipient becomes aware that the funds provided under this agreement are in fact or are anticipated to be materially higher than this amount, the Principal Recipient shall promptly notify the Global Fund.

4. The parties acknowledge and agree that should the Global Fund fail to receive:

- a. Complete and accurate data on expenditures by the Government of Sao Tome and Principe towards the fight against HIV during the year 2011; and
- b. Adequate assurances that, beginning in 2012 and continuing throughout the Program Term, funding for the fight against HIV in Sao Tome and Principe by the Government of Sao Tome and Principe will comprise at least thirty-five percent of all such funding

from the Country Coordinating Mechanism on or before by 28 February 2012, the Global Fund may take appropriate action pursuant to the terms of this Agreement, including, without limitation, reducing or withholding disbursements.

5. The parties acknowledge and agree that as of the date of the signature of this Agreement, the reporting schedule is set on a 6-monthly basis for each Progress Update

and Disbursement Request. The parties further agree and acknowledge that should the Global Fund determine, after consulting with the Principal Recipient, that the results of the 2012 On-Site Data Verification report demonstrate major issues in data quality, the Global Fund may re-set the reporting schedule for Progress Updates to a quarterly basis.

6. The Principal Recipient acknowledges and agrees that the Principal Recipient's selection of an appropriately qualified individual to serve as the HIV/AIDS and Tuberculosis program Manager shall be based on terms of reference mutually agreed to between the Global Fund and the Principal Recipient.

**D. FORMS APPLICABLE TO THIS AGREEMENT**

For purposes of Article 13b(1) of the Standard Terms and Conditions of this Agreement entitled "Quarterly Reports," the Principal Recipient shall use the "On-going Progress Update and Disbursement Request", available from the Global Fund upon request and Article 13b.(2) (Annual Report) is deleted.

**E. ANTICIPATED DISBURSEMENT SCHEDULE**

For the purposes of Article 6a. of the Standard Terms and Conditions of this Agreement, the anticipated disbursement schedule is that indicated in the Performance Framework attached to this Annex A.

**F. PROGRAM BUDGET**

The Summary Budget attached to this Annex A sets forth anticipated expenditures for the Program term.

**G. PERFORMANCE FRAMEWORK**

The Performance Framework attached to this Annex A sets forth the main objectives of the Program, key indicators, intended results, targets and reporting periods of the Program.

**SUMMARY BUDGET Year 1 & 2**  
(formerly Attachment A)

**HIV AIDS**

<b>Program Details</b>	
Country	Sao Tome and Principe
Grant No	STP-011-005-H
PR	United Nations Development Programme (UNDP)
Currency	USD
Grant Cycle phase	Phase 1

Please indicate Periods covered by this budget in the cells below, as presented in the Performance Framework.

	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8
Period Covered: from	1-Jan-12	1-Apr-12	1-Jul-12	1-Oct-12	1-Jan-13	1-Apr-13	1-Jul-13	1-Oct-13
Period Covered: to	31-Mar-12	30-Jun-12	30-Sep-12	30-Dec-12	31-Mar-13	30-Jun-13	30-Sep-13	31-Dec-13

**A. SUMMARY BUDGET BREAKDOWN BY EXPENDITURE CATEGORY**

#	Category	Year1				Total Year1	Year2				Total Year2	N/A	O AL Phase 1	%
		Q1	Q2	Q3	Q4		Q5	Q6	Q7	Q8				
####	Human Resources	9,338	9,338	17,588	17,588	53,851	69,195	69,195	34,790	17,588	190,767		244,618	23%
####	Technical and Management Assistance	13,664	12,835	11,780	0	38,279	5,890	0	0	0	5,890		44,169	4%
####	Training	2,692	19,313	97,182	11,205	130,392	26,999	20,885	8,641	12,906	69,431		199,823	18%
####	Health Products and Health Equipment	34,306	15,322	0	0	49,629	64,075	0	0	0	64,075		113,704	11%
####	Pharmaceutical Products (Medicines)	19,867	22,182	0	0	42,049	20,202	38,596	0	0	58,798		100,847	9%
####	Procurement and Supply Management Costs (PSM)	6,434	9,449	2,094	2,057	20,035	6,147	12,695	2,242	2,205	23,289		43,324	4%
7	Infrastructure and Other Equipment	48,696	10,000	0	0	58,696	3,388	0	0	0	3,388		62,085	6%
8	Communication Materials	15,783	0	0	0	15,783	1,544	0	0	0	1,544		17,327	2%
9	Monitoring and Evaluation (M&E)	5,884	6,233	9,782	42,274	64,173	6,621	6,621	31,341	6,621	51,205		115,378	11%
10	Living Support to Clients/Target Population	5,619	5,619	5,619	5,619	22,475	6,421	6,421	6,421	6,421	25,685		48,160	4%
11	Planning and Administration	1,850	1,250	1,250	1,250	5,600	4,514	1,250	1,250	1,250	8,264		13,864	1%
12	Overheads	10,534	8,828	10,534	8,918	38,814	10,836	8,861	10,836	8,937	39,471		78,284	7%
13	Other	0	0	0	0	0	0	0	0	0	0		0	0%
<b>O AL</b>		<b>174,866</b>	<b>120,368</b>	<b>155,829</b>	<b>88,911.05</b>	<b>539,774</b>	<b>225,832</b>	<b>164,524</b>	<b>95,522.16</b>	<b>55,929</b>	<b>541,808</b>		<b>1,081,582</b>	<b>100%</b>

**B. SUMMARY BUDGET BREAKDOWN BY PROGRAM ACTIVITY**

#	Macro category	Objectives	Service Delivery Area	Year1				Total Year1	Year2				Total Year2	N/A	O AL Phase 1	%
				Q1	Q2	Q3	Q4		Q5	Q6	Q7	Q8				
1	HIV:Prevention	Prevention HIV/AIDS	1-Testing and Counseling	15,134	4,081	1,523	3,132	23,870	17,582	0	0	0	17,582		41,452	4%
2	HIV:Prevention	Prevention HIV/AIDS	2-STI diagnosis and treatment	32	1,243	0	0	1,276	1,162	4,083	1,566	4,083	10,894		12,170	1%
3	HIV:Prevention	Prevention HIV/AIDS	3-BCC - community outreach and Most-at-risk population	15,843	1,869	35,477	5,117	58,307	1,558	1,869	4,941	5,117	13,486		71,793	7%
4	HIV:Prevention	Prevention HIV/AIDS	5-Condom	7,798	1,021	1,021	1,021	10,862	4,410	1,021	11,554	1,021	18,006		28,869	3%
5	HIV:Treatment	Treatment	6-Antiretroviral treatment (ARV) and monitoring	42,735	23,471	0	0	66,206	14,080	46,756	0	0	60,836		127,042	12%
6	HIV:Prevention	Prevention HIV/AIDS	7-Prophylaxis and treatment for opportunistic infections	15,240	2,286	22,000	0	39,526	20,172	2,292	0	0	22,464		61,990	6%
7	HIV:Prevention	Prevention HIV/AIDS	8-TB/HIV	1,262	0	0	0	1,262	176	0	0	0	176		1,439	0%
8	HIV:Treatment	Treatment	9-Care and support for the chronically ill	6,494	4,521	5,345	4,173	20,534	5,207	1,865	0	0	7,071		27,605	3%
9	HIV:Treatment	Treatment	10-Support for orphans and vulnerable children	5,619	5,619	5,619	5,619	22,475	6,421	6,421	6,421	6,421	25,685		48,160	4%
10	HIV:Care and Support	Life quality amelioration	11-PMTCT	3,275	2,985	6,108	5,086	17,453	19,508	2,983	2,983	3,990	29,465		46,918	4%
11	HIV:Care and Support	Life quality amelioration	12-Blood safety and universal precaution	12,308	28,111	33,471	1,200	75,090	46,684	1,200	4,948	1,200	54,032		129,122	12%
12	HIV:Care and Support	Life quality amelioration	13-Programme management and Administration cost	24,727	23,498	20,958	19,439	88,622	74,219	83,355	38,161	19,424	215,160		303,782	28%
12	HIV:Care and Support	Life quality amelioration	14-HSS: Informat on system	2,829	0	5,884	35,296	44,008	3,816	3,816	14,112	5,810	27,555		71,563	7%
12	HIV:Care and Support	Life quality amelioration	15-Strengthening of civil society and institutional capacity building	10,835	12,835	7,890	0	31,560	0	0	0	0	0		31,560	3%
12	HIV:Care and Support	Life quality amelioration	16-Contribution	10,534	8,828	10,534	8,828	38,723	10,836	8,861	10,836	8,861	39,395		78,118.30	7%
<b>O AL</b>		<b>174,665.9</b>	<b>120,368.5</b>	<b>155,828.7</b>	<b>88,911.1</b>	<b>539,774.2</b>	<b>225,832.3</b>	<b>164,524.322</b>	<b>95,522.392</b>	<b>55,929.101</b>	<b>541,808.144</b>		<b>1,081,582</b>	<b>1.0</b>		

To add additional rows, right click the row number (Row 1 in a blank template) to the left of the row above the row for TOTAL and select copy, then over the same number, right click again and select Insert Copied Cells. WARNING: Inserting Rows without copying a row as described above will cause the formula in the columns to become invalid and will mean the overall information will be inaccurate.



**C. SUMMARY BUDGET BREAKDOWN BY IMPLEMENTING ENTITY (if known by Grant signature time)**

#	PR/SR	Name	Type of Implementing Entity	Year1				Total Year1	Year 2				Total Year2	N/A	O AL Phase 1	%
				Q17	Q18	Q19	Q20		Q5	Q6	Q7	Q8				
SR		NAP	Ministry of Health (MoH)	21,272	18,916	56,597	41,957	138,743	21,488	15,930	15,436	5,524	58,378		197,121	18%
SR		ISVSM	Ministry of Health (MoH)	3,617	1,912	13,148	6,204	24,881	12,573	6,615	7,957	9,043	36,189		61,069	6%
SR		FNM	Ministry of Health (MoH)	2,656	6,983	228	228	10,095	770	10,680	228	228	11,906		22,001	2%
SR		Alisel	NGO/CBO/Academic	7,798	2,891	36,498	2,891	50,078	4,410	2,891	16,495	2,891	26,686		78,764	7%
SR		OMS	Other Multilateral Organisation	10,835	12,835	20,030	8,250	51,950	14,140	8,250	8,250	8,250	38,890		90,840	8%
SR		Cruz Vermelha	NGO/CBO/Academic	4,173	4,173	4,173	4,173	16,693	0	0	0	0	0		16,693	2%
SR		Caritas	NGO/CBO/Academic	5,619	5,619	5,619	5,619	22,475	6,421	6,421	6,421	6,421	25,685		48,160	4%
SR		UNDABESA	Ministry of Health (MoH)	1,200	1,200	1,200	1,200	4,800	1,200	1,200	1,200	1,200	4,800		9,600	1%
PR		UNDP	UNDP	117,495	65,840	18,336	18,389	220,060	164,829	112,537	39,536	22,372	339,274		559,334	52%
<b>O AL*</b>				<b>174,666</b>	<b>120,368</b>	<b>155,829</b>	<b>88,911.05</b>	<b>539,774</b>	<b>225,832.26</b>	<b>164,524.45</b>	<b>95,522.39</b>	<b>55,928.74</b>	<b>541,807.84</b>		<b>1,081,582</b>	<b>100%</b>

To add additional rows, right click the row number (Row 56 in a blank template) to the left of the row above the row for TOTAL and select copy, then over the same number, right click again and select Insert Copied Cells. WARNING: Inserting Rows without copying a row as described above will cause the formula in the columns to become invalid and will mean the

\* The sum of all three breakdowns should be equal (A: Budget Line-Item, B: Program Activity, C: Implementing Entity).

\*\* For the purposes of this report, the SDA Program management and administration should be included in the Supportive Environment Macro Category.



Indicator Number	Objective Number	Service Delivery Area	Indicator formulation	Baseline (if applicable)			Periodical targets for year 1 & 2										Tied to	Targets cumulative Y-over program term Y-cumulative annually N-not cumulative	Baselines included in targets (Y/N)	Top 10 indicator	Comments
				Value	Year	Source	P1 (Jan-June 2012)		P2 (July-Dec 2012)		P3 (Jan-June 2013)		P4 (July-Dec 2013)		P5*						
							Jan March 2012	April June 2012	July Sept 2012	Oct Dec 2012	Jan March 2013	April June 2013	July Sept 2013	Oct Dec 2013		Jan Mar 2014					
1	1	Testing and Counseling	Number of <b>men</b> who received testing and counseling services for HIV and received their test results	3316	2010	PNLS REPORT	840	1680	2520	5860	1565	3130	4695	9760	1565	National Program	Y - cumulative annually	N	Top 10	GFATM is mainly funding RDT for testing of blood donors and general population. This indicator includes cases tested at community level.	
2	1	Testing and Counseling	Number of <b>women</b> who received testing and counseling services for HIV and received their test results	11047	2010	PNLS REPORT	2770	5540	8310	13080	3085	6170	9255	15340	3085	National Program	Y - cumulative annually	N	Top 10	This includes all women, including those tested in ANC. GF is funding RDTs.	
3	1	BCC - community outreach and schools	Number of sex workers reached through community outreach with at least one HIV information, education, communication or behavior change communication	54	2007-2010	SR report (NGO Alisei)		18	36	54	18	36	54	72	18	Current grant	Y - cumulative annually	N	Top 10	Phase 2 should include targets for reaching MSM - strategy to be developed by year 2. Baseline includes the number of sex workers identified during 2007-2010 and trained to be peer educators. Current population estimate is approximately 70 sex workers, with additional outreach and identification expected. System for avoiding double counting is in place within each year.	
4	2	Antiretroviral treatment (ARV) and monitoring	Number of people with advanced HIV+ infection receiving ARV treatment (second line) according to national guidelines	16	2010	PNLS REPORT		42		45		47		49	50	Current grant	N - not cumulative	Y	Top 10	This includes all patients on second-line treatment who are in the active file (e.g., excluding deaths and lost to follow-up). First-line treatment is supported through the Brazilian Cooperation. The targets are based on total need for second line treatment, calculated from patient cohorts enrolled on treatment from 2005 to 2010, as identified in a 2011 study.	
5	2	TB/HIV	Number and percentage of TB patients who had an HIV test result recorded in the TB register among the total number of registered TB patients	100% (112)	2010	PNLT REPORT		100% (56)		100% (60)		100% (56)		100% (60)	100% (28)	National Program	N - not cumulative	N	Top 10	The GF contribution is estimated to be around 30%  Numerator: the total number of TB patient recorded by the NTBP tested to HIV antibody, during the period (quarterly or annually)  Denominator: the total number of TB patient recorded by the NTBP (clinically or biologically) , during the period (quarterly or annually)	
6	2	Prophylaxis and treatment for opportunistic infections	Number of HIV+ patients receiving cotrimoxazole prophylaxis for opportunistic infections	152	2010	PNLS REPORT		18		38		18		38	9	Current grant	Y - cumulative annually	N	Not Top 10	In 2010, approximately 453 people living with HIV in country, 200 under ARVs, and others in registered in care. 8% annually are in need of cotrimoxazole prophylaxis. GF contribution is 100%	
7	2	Support for orphans and vulnerable children	Number of orphans receiving package of services	35	2010	SR Report				35				40		Current grant	Y - cumulative annually	N	Top 10	GF contribution is 100%. Package of services includes school uniform, school materials, and food support during at least 80% of periods eligible, plus contribution to school fees. WFP is now covering food support only for adults.	
8	3	PMTCT	Number and percentage of infants born to HIV-infected women who received an HIV test within 12 months of birth	NA	2010	NAP report		7		13/15 (86%)		7		14/15 (93%)	3	National Program	Y - cumulative annually	N	Not Top 10	GF contribution is estimated to be around 50%  Numerator: children born to HIV infected mothers that were tested for HIV antibody between 9 and 12 months of age.  Denominator: all HIV infected pregnant women giving birth in the last 12 months at health service (all PW are tested at delivery for HIV).	
9	3	PMTCT	Number and percentage of infants born to HIV-infected women starting on co-trimoxazole prophylaxis within 2 months of birth	NA	NA	NAP report		6		15 (100%)		6		15 (100%)		Current grant	Y - cumulative annually	N	Not Top 10		
10	4	Blood safety and universal precaution	Number of health care workers trained on universal precautions	264	2010	Training records				20		60		100		Current grant	Y - cumulative annually	N	Not Top 10		
11	5	HSS: Information system	Number of health districts providing complete and timely reports	0	2011	NAP report		4		5		6		7	7	National Program	N - not cumulative	N	Not Top 10	Timely: to be received before the 16th of the month of the reporting period; Complete: to include at least 10 key indicator from the existing form. Total of 7 districts in the country.	

## **Standard Terms and Conditions**

### **Article 1. PURPOSE OF AGREEMENT**

This Agreement between the Global Fund to Fight AIDS, Tuberculosis and Malaria, a non-profit foundation established under the laws of Switzerland (the “Global Fund”) and the United Nations Development Programme, a subsidiary organ of the United Nations, with its headquarters in New York, New York, United States of America, as represented by its Resident Representative in the country specified in block 1 of the face sheet of this Agreement (the “Principal Recipient”) defines the terms and conditions under which the Global Fund will provide funding to the Principal Recipient to implement or oversee the implementation of the Program whose title is set forth in block 2 of the face sheet of this Agreement (the “Program”) for the country specified in block 1 of the face sheet of this Agreement (“Host Country”).

### **Article 2. THE PROGRAM**

a. The Program is further described in Annex A of this Agreement, the “Program Implementation Abstract.” The Principal Recipient will implement or oversee the implementation of the Program in accordance with the terms of this Agreement, which the Principal Recipient will administer using its regulations, rules and procedures. The Principal Recipient will be responsible and accountable to the Global Fund for all resources it receives under this Agreement and for the results that are to be accomplished.

b. The Global Fund and the Principal Recipient may by agreement in writing from time to time modify Annex A of this Agreement during the implementation of the Program.

### **Article 3. FISCAL TERMS**

a. The Global Fund hereby grants to the Principal Recipient an amount not to exceed that stated in block 7 of the face sheet of this Agreement (the “Grant”), which shall be made available to the Principal Recipient under the terms of this Agreement. The Global Fund makes the Grant to the Principal Recipient in response to the Country Coordinating Mechanism’s request for financial assistance.

b. Any interest or other earnings on funds disbursed by the Global Fund to the Principal Recipient under this Agreement shall be used for Program purposes, unless the Global Fund agrees otherwise in writing.

c. (1) Total Global Fund funding for the Program is limited to the Grant. Each disbursement of Grant funds shall be subject to the availability of funds to the Global Fund for such purpose at the time of the disbursement. Unless the Global Fund agrees otherwise in writing, the Grant may be used for Program expenditures beginning from the “Program Starting Date” (specified in block 4 of the face sheet of this Agreement). If the Principal Recipient chooses to continue Program activities after the Global Fund funding has been exhausted, the Principal Recipient understands that the Global Fund makes no commitment beyond the amounts available under the terms of this Agreement.

(2) In making funds available for the Program, the Global Fund acknowledges that, in accordance with the Principal Recipient's Financial Regulations and Rules, disbursements to the Principal Recipient must be made in advance of the implementation of the activities to be financed. In the event funds are not available to the Global Fund, the Principal Recipient may reduce, suspend or terminate its support to the Program.

d. The Global Fund and the Principal Recipient estimate that the proposal described in Annex B, as designed and if fully funded and implemented, will be completed by the "Proposal Completion Date" (specified in block 6 of the face sheet of this Agreement). Unless the Global Fund agrees otherwise in writing, the Global Fund will not authorize disbursement of the Grant after the "Program Ending Date" (specified in block 5 of the face sheet of this Agreement) if the Global Fund determines in its sole discretion that satisfactory progress has not been made in implementing the Program before the Program Ending Date or that funds are not available for such disbursement.

e. Conditions Precedent to Disbursement.

(1) Annex A, the Program Implementation Abstract, may state conditions precedent to first disbursement of funds under the Grant or conditions precedent to disbursement of Grant funds for a particular purpose, in excess of a specified amount or after a certain time. Unless the Global Fund and the Principal Recipient agree otherwise in writing, the Principal Recipient must satisfy the stated conditions, in form and substance satisfactory to the Global Fund, before the Global Fund will authorize disbursement of the relevant funds.

(2) The terminal dates for meeting the conditions specified in Annex A are the dates specified in blocks 6A, 6B and 6C (if present) of the face sheet of this Agreement, as indicated for the particular conditions. If the conditions precedent have not been met by the stated terminal date, the Global Fund, at any time, may terminate this Agreement by written notice to the Principal Recipient.

(3) Unless the Global Fund advises the Principal Recipient otherwise in writing, the Principal Recipient will furnish to the Global Fund all items required to satisfy the conditions precedent to disbursement stated in Annex A and shall ensure that members of the Country Coordinating Mechanism receive copies of the items. The Global Fund will promptly notify the Principal Recipient when the Global Fund has determined that a condition precedent has been met.

f. Consistent with numerous United Nations Security Council Resolutions, including S/RES/1269 (1999), S/RES/1368 (2001), and S/RES/1373 (2001), both the Global Fund and the Principal Recipient are firmly committed to the international fight against terrorism, and in particular, against the financing of terrorism. It is the policy of the Global Fund to seek to ensure that none of its funds are used, directly or indirectly, to provide support to individuals or entities associated with terrorism. In accordance with this policy, the Principal Recipient undertakes to use reasonable efforts to ensure that none of the Grant funds provided under this Agreement are used to provide support to individuals or entities associated with terrorism.

#### **Article 4. TAXES AND DUTIES**

a. The Principal Recipient shall try to ensure through coordination with the government of the Host Country and the Country Coordinating Mechanism and otherwise that this Agreement and the assistance financed hereunder shall be free from taxes and duties imposed under laws in effect in the Host Country.

b. The Principal Recipient shall assert all exemptions from taxes and duties to which it believes it, the Global Fund or the Grant is entitled.

#### **Article 5. THE TRUSTEE**

The Global Fund and the International Bank for Reconstruction and Development (the "World Bank") have entered into an agreement as of May 31, 2002, by which the World Bank has agreed to establish the "Trust Fund for the Global Fund to Fight AIDS, Tuberculosis and Malaria" (the "Trust Fund") and to serve as the trustee of the Trust Fund (the "Trustee"). Grant funds made available to the Principal Recipient will be disbursed from the Trust Fund.

#### **Article 6. DISBURSEMENTS**

a. Approximately every three months, the Principal Recipient shall submit to the Global Fund requests for disbursements of funds from the Grant, in form and substance satisfactory to the Global Fund. Requests for disbursement shall be signed by the person or persons authorized by the Principal Recipient to do so. Upon the Global Fund's approval of a request for disbursement, the Global Fund will advise the Trustee to transfer the amount approved by the Global Fund into the account specified in block 9 of the face sheet of this Agreement.

b. The amount approved for disbursement will be based on achievement of Program milestones and the expected cash flow needs of the Principal Recipient. The Global Fund, at any time, may approve for disbursement an amount less than the disbursement request if the Global Fund concludes that the full disbursement request is not justified.

c. Each disbursement under the Grant is subject to the availability of funds to the Global Fund for such disbursement.

#### **Article 7. AUDITS AND RECORDS**

a. Books and Records of the Principal Recipient.

The Principal Recipient shall maintain Program accounts, books, records, and all other documents relating to the Program or maintained under the Agreement, adequate to show, without limitation, all costs incurred by the Principal Recipient under the Agreement and the overall progress toward completion of the Program ("Program books and records"). The Principal Recipient shall maintain Program books and records in accordance with United Nations Accounting Standards. Program books and records shall be maintained for at least three years after the date of last disbursement under this Agreement or for such longer period, if any, required to resolve any claims or audit findings.

b. Principal Recipient Audits.

The Principal Recipient shall have financial audits conducted of Program expenditures in accordance with its internal and external auditing practices. The Principal Recipient agrees to provide to the Global Fund a copy of biennial financial statements, as audited by its external auditors, the UN Board of Auditors.

c. Certified Financial Statement.

Not later than June 30 of each year, the Principal Recipient shall submit to the Global Fund a statement, certified by the Comptroller of the Principal Recipient, of income and expenditure of the Program during the preceding year.

d. Sub-recipient Audits.

The Principal Recipient shall submit to the Global Fund a plan, acceptable to the Global Fund, for the audit of the expenditures of Sub-recipients under the Program. The Principal Recipient shall ensure that Sub-recipients are audited in accordance with the plan, unless the Global Fund and the Principal Recipient agree otherwise in writing. Upon request, the Principal Recipient shall furnish or cause to be furnished to the Global Fund a copy of reports of audits carried out under the plan.

e. Ad-hoc Site Visits

The Principal Recipient shall afford authorized representatives of the Global Fund and its agents or any third party of which the Global Fund notifies the Principal Recipient the opportunity at all reasonable times on an ad hoc basis to make visits related to operations financed by the Grant. The purpose of such ad hoc site visits is to allow the Global Fund to be in a position to report to its constituencies on the implementation of the Program and to determine whether value for money has been obtained. In connection with such visits, the Principal Recipient will make available to the Global Fund all relevant financial information drawn from the relevant accounts and records.

f. Notification.

The Principal Recipient shall notify the Global Fund promptly in writing of any audits of activities financed by this Agreement initiated by or at the request of an audit authority of the Government of the Host Country or of any other entity.

**Article 8. REFUNDS**

a. In the case of any disbursement of the Grant that is not made or used in accordance with this Agreement, or that finances goods or services that are not used in accordance with this Agreement, the Global Fund, notwithstanding the availability or exercise of any other remedies under this Agreement, may require the Principal Recipient to refund the amount of such disbursement in United States dollars to the Global Fund within sixty (60) days after the Principal Recipient receives the Global Fund's request for a refund.

b. If the Principal Recipient's failure to comply with any of its obligations under this Agreement has the result that goods or services financed or supported by the Grant are not

used in accordance with this Agreement, the Global Fund may require the Principal Recipient to refund all or any part of the amount of the disbursements under this Agreement for or in connection with such goods or services in United States dollars to the Global Fund within sixty (60) days after receipt of a request therefor.

c. The right under paragraphs (a) or (b) of this Article to require a refund of a disbursement will continue, notwithstanding any other provision of this Agreement, for three years from the date of the last disbursement under this Agreement.

## **Article 9. ADDITIONALITY**

In accordance with the criteria governing the selection and award of this Grant, the Global Fund has awarded the Grant to the Principal Recipient on the condition that the Grant is in addition to the normal and expected resources that the Host Country usually receives or budgets from external or domestic sources. In the event such other resources are reduced to an extent that it appears, in the sole judgment of the Global Fund, that the Grant is being used to substitute for such other resources, the Global Fund may terminate this Agreement in whole or in part under Article 21 of this Agreement.

## **Article 10. PROGRAM COOPERATION AND COORDINATION**

### **a. The Country Coordinating Mechanism**

(1) The Principal Recipient hereby acknowledges that:

(a) the Country Coordinating Mechanism (of which the Principal Recipient is a part) is the group that coordinates the submission of proposals to the Global Fund from the Host Country and monitors the implementation of activities under approved programs;

(b) the Country Coordinating Mechanism functions as a forum to promote true partnership development and participation of multiple constituencies, including Host Country governmental entities, donors, nongovernmental organizations, faith-based organizations and the private sector;

(c) the Country Coordinating Mechanism should encourage multisectoral program approaches and ensure linkages and consistency between Global Fund assistance and other development and health assistance programs, including but not limited to multilateral loans, bilateral grants, Poverty Reduction Strategy Programs, and sector-wide assistance programs; and

(d) the Country Coordinating Mechanism should encourage its partners to mobilize broadly to fight diseases of poverty, to seek increased financial resources and technical assistance for that purpose, and to ensure the sustainability of local programs, including those supported by the Global Fund.

(2) The Principal Recipient will cooperate with the Country Coordinating Mechanism and the Global Fund to assure that the purpose of this Agreement will be accomplished. To this end, the Principal Recipient and the Global Fund, at the request of either or of the Country Coordinating Mechanism, will exchange views on the progress of the



Program, the performance of obligations under this Agreement, and the performance of any consultants, contractors, or suppliers engaged in the Program, and other matters relating to the Program.

(3) The Principal Recipient shall actively assist the Country Coordinating Mechanism to meet regularly to discuss plans, share information and communicate on Global Fund issues. The Principal Recipient shall keep the Country Coordinating Mechanism continuously informed about the Program and the Principal Recipient's management thereof and shall furnish to the Country Coordinating Mechanism such reports and information as the Country Coordinating Mechanism may reasonably request. The Principal Recipient understands that the Global Fund may, in its discretion, share information with the Country Coordinating Mechanism.

(4) The Principal Recipient shall coordinate its activities with the activities of related or substantially similar programs in the Host Country.

(5) The Global Fund and the Principal Recipient may agree in Implementation Letters, in accordance with Article 12 below, on additional responsibilities of the Principal Recipient with respect to the Country Coordinating Mechanism.

**b. Sub-recipients**

(1) From time to time, the Principal Recipient may, under this Agreement, provide funding to other entities to carry out activities contemplated under the Program ("Sub-recipients"). The Principal Recipient will be responsible for the results it and Sub-recipients (if any) are to accomplish. The Principal Recipient shall ensure that all agreements with Sub-recipients ("Sub-recipient Agreements") are consistent with this Agreement. Prior to any disbursement of Grant funds to a Sub-recipient, the Principal Recipient shall obtain and maintain in effect a certification from such Sub-recipient that such Sub-recipient shall (i) undertake best efforts to ensure that none of the Grant funds received by it are used to provide support to individuals or entities associated with terrorism and that the recipients of any amounts provided by the Principal Recipient under the Sub-recipient Agreement do not appear on the list maintained by the Security Council Committee established pursuant to resolution 1267 (1999); and (ii) ensure that the same undertaking is included in all sub-contracts or sub-agreements entered into under the Sub-recipient Agreement. The Principal Recipient shall furnish the Global Fund a copy of the form or forms of agreement, acceptable to the Global Fund, that the Principal Recipient will use with Sub-recipients.

(2) The Principal Recipient's accountability and reporting shall encompass the funds disbursed to all Sub-recipients and to the activities Sub-recipients carry out using Program funds. The Principal Recipient shall have systems in place to assess (before the Principal Recipient transfers any resources to a Sub-recipient) the capacity of Sub-recipients, monitor their performance, and assure regular reporting from them in accordance with this Agreement. The Principal Recipient shall comply with such systems to assess Sub-recipients and supervise and monitor their activities and reporting under the Program. If the Principal Recipient finds that a Sub-recipient does not possess the required capacity to carry out the activities envisioned under the Program, the Principal Recipient will consult with the Country Coordinating Mechanism and the Global Fund about how the situation should most appropriately be addressed.

(3) With respect to Sub-recipients or other third parties that enter into agreements with the Principal Recipient, the Global Fund shall assume no responsibility for the actions of such Sub-recipients or other third parties.

**c. Other Principal Recipients**

In addition to the Principal Recipient, the Global Fund may from time to time award grants to other entities, as possibly proposed by the Country Coordinating Mechanism, to implement programs in the Host Country. The Principal Recipient will cooperate as appropriate with such other entities to realize the benefits of all programs financed by the Global Fund.

**d. The LFA**

(1) The Global Fund has entrusted an entity, as indicated in block 11 of the face sheet of this Agreement, (the “LFA”), to assist the Global Fund in its oversight role during the implementation of the Program.

(2) The Principal Recipient shall cooperate fully with the LFA to permit the LFA to carry out its functions. To this end, the Principal Recipient shall, inter alia, do the following, unless the Global Fund specifies otherwise in writing:

(a) submit all reports, disbursement requests and other communications required under this Agreement to the Global Fund through the LFA;

(b) submit to the LFA copies of all audit reports required under Article 7.d of this Agreement;

(c) permit the LFA to perform ad hoc site visits at the times and places decided by the LFA; and

(d) cooperate with the LFA in other ways that the Global Fund may specify in writing.

(3) For purposes of this Agreement, the principal representative of the LFA shall be the person named or acting in the position identified in block 11 of the face sheet of this Agreement, unless the Global Fund notifies the Principal Recipient otherwise in writing.

**Article 11. COMMUNICATIONS**

Any notice, request, document, report, or other communication submitted by either the Principal Recipient or the Global Fund, unless this Agreement expressly provides otherwise or the Global Fund and the Principal Recipient agree otherwise in writing, will be sent to the other party’s Authorized Representative (noted in block 15 or 16 of the face sheet of this Agreement) or Additional Representative (noted in block 12 or 13 of the face sheet of this Agreement). In the case of communications to the Global Fund through the LFA, the Principal Recipient shall submit such communications to the person identified in block 11 of the face sheet of this Agreement. All communications under this Agreement will be in English, unless the Global Fund and the Principal Recipient agree otherwise in writing.

## **Article 12. IMPLEMENTATION LETTERS**

To assist the Principal Recipient in the implementation of this Agreement, the Global Fund will from time to time issue Implementation Letters that will furnish additional information and guidance about matters stated in this Agreement. In addition, the Global Fund and the Principal Recipient may from time to time issue jointly signed Implementation Letters to confirm and record their mutual understanding on aspects of the implementation of this Agreement.

## **Article 13. REPORTS**

a. Unless the Global Fund advises the Principal Recipient otherwise in writing, the Principal Recipient shall furnish to the Global Fund the reports specified in paragraph b below at the interval indicated or such other interval to which the Global Fund and the Principal Recipient may agree in writing. The reports shall cover all funds and activities financed under the Grant. In addition, the Principal Recipient shall furnish to the Global Fund such other information and reports at such times as the Global Fund may request. The Global Fund will from time to time specify in Implementation Letters the guidelines for the contents and formats of the reports. The Principal Recipient shall furnish to the Country Coordinating Mechanism a copy of all reports the Principal Recipient submits to the Global Fund.

### **b. Required Reports**

#### **(1) Quarterly Reports**

Not later than 45 days after the close of each quarter of the Principal Recipient's fiscal year, the Principal Recipient shall submit to the Global Fund, in form and substance satisfactory to the Global Fund, a periodic report on the Program. The report shall reflect (i) financial activity during the quarter in question and cumulatively from the beginning of the Program until the end of the reporting period; and (ii) a description of progress towards achieving the agreed-upon milestones set forth in Annex A. The Principal Recipient shall explain in the report any variance between planned and actual achievements for the period in question.

#### **(2) Annual Reports**

Not later than 45 days after the close of each fiscal year of the Principal Recipient, the Principal Recipient shall submit to the Global Fund, in form and substance satisfactory to the Global Fund, an annual financial and programmatic monitoring report (in addition to the quarterly reports) covering the preceding fiscal year.

#### **(3) Phase Two Reporting**

The Principal Recipient shall cooperate with the Global Fund, the Country Coordinating Mechanism, and other actors as necessary and appropriate to provide for the timely filing of an application for the continuation of funding beyond the Program End Date.

## **Article 14. MONITORING**

The Principal Recipient will follow a principle of results-based monitoring congruent with the Global Fund's results-based disbursement approach. Not later than 90 days after this Agreement enters into force, the Principal Recipient shall submit to the Global Fund, in form and substance satisfactory to the Global Fund, a detailed plan for monitoring the Program. The Global Fund will specify in Implementation Letters the guidelines for the plan.

**Article 15. EVALUATION**

The Global Fund, in its discretion, may conduct an independent evaluation of the Program. The Global Fund evaluation will conform to international best practice standards that include a focus on results, transparency and substantive accountability. The Global Fund will collaborate with the Evaluation Office of the Principal Recipient to specify, in consultation with the Country Coordinating Mechanism, the terms of reference for the evaluation and to plan, schedule and implement the evaluation. The Principal Recipient shall require all Sub-recipients to cooperate fully in the execution of the evaluation. The Global Fund will provide the Principal Recipient with a copy of the report of the evaluation.

**Article 16. DISSEMINATION OF INFORMATION**

The Global Fund and the Principal Recipient may make the information derived from the implementation of this Program available to the domestic and international community, consistent with the rights of individuals to privacy, the property rights of persons in trade secrets and confidential commercial or financial information. The Global Fund reserves the right to freely publish or disseminate information derived from the implementation of this Program.

**Article 17. CONTRACTS FOR GOODS AND SERVICES.**

a. Unless the Global Fund agrees otherwise in writing, the Principal Recipient shall disclose to the Global Fund the policies and practices that it will use to contract for goods and services under this Agreement. At a minimum, such policies and practices shall conform to requirements 1 through 5 listed below.

- (1) Contracts shall be awarded, to the extent practical, on a competitive basis.
- (2) Solicitations for goods and services shall be based upon a clear and accurate description of the goods or services to be acquired.
- (3) Contracts shall be awarded only to responsible contractors that possess the potential ability to successfully perform the contracts.
- (4) No more than a reasonable price (as determined, for example, by a comparison of price quotations and market prices) shall be paid to obtain goods and services.
- (5) The Principal Recipient shall maintain records regarding the receipt and use of goods and services acquired under the Agreement by the Principal Recipient, the nature and extent of solicitations of prospective suppliers of goods and services acquired by the Principal Recipient, and the basis of award of Principal Recipient contracts and orders.

b. Title to goods or other property financed under this Agreement shall be in the name of the Principal Recipient or such other entity as the Principal Recipient may designate and shall be disposed of by the Principal Recipient during the life of the Program or at its completion in accordance with Article 19 below.

c. From time to time, the Global Fund will issue Implementation Letters to further advise the Principal Recipient regarding policies applicable to contracts for goods and services using Grant funds.

## **Article 18. PHARMACEUTICAL AND OTHER HEALTH PRODUCTS**

a. Definitions. As used in this Article, the following terms shall have the meanings given to them below:

**Available** means that the manufacturer of the relevant product can supply the requested quantity of the product within 90 days of the requested delivery date.

**Expert Review Panel (ERP)** means a panel of independent experts which reviews the potential risks/benefits associated with the use of Finished Pharmaceutical Products and makes recommendations to the Global Fund as to whether such Finished Pharmaceutical Products may be procured with Grant funds. A Finished Pharmaceutical Product will be eligible for review by the Expert Review Panel if it has not yet been prequalified by the WHO or authorized for use by a Stringent Drug Regulatory Authority, but meets the following criteria:

- (a)
  - (i) the manufacturer of the Finished Pharmaceutical Product has submitted an application for prequalification of the product by the WHO Prequalification Programme and it has been accepted by WHO for review; or
  - (ii) the manufacturer of the Finished Pharmaceutical Product has submitted an application for marketing authorization to a Stringent Drug Regulatory Authority, and it has been accepted for review by the Stringent Drug Regulatory Authority, and
- (b) the Finished Pharmaceutical Products is manufactured at a site that is compliant with the GMP standards that apply for the relevant Product Formulation, as verified after inspection by:
  - (i) the WHO Prequalification Programme;
  - (ii) a Stringent Drug Regulatory Authority; or
  - (iii) a drug regulatory authority participating to the Pharmaceutical Inspection Cooperation Scheme.

**ERP Recommendation Period** means the period during which an Expert Review Panel recommendation for the use of a particular Finished Pharmaceutical Product remains in full force and effect. If the Expert Review Panel recommends the use of a Finished Pharmaceutical Product, the recommendation shall be valid for an initial period of no more than 12 months or until the Finished Pharmaceutical Product is prequalified by the WHO or authorized for use by a Stringent Drug Regulatory Authority, whichever is earlier. The Global Fund may, in its sole discretion, request the Expert Review Panel to consider extending the ERP Recommendation Period.

**Finished Pharmaceutical Product** means a medicine presented in its finished dosage form that has undergone all stages of production, including packaging in its final container and labeling.

**Good Manufacturing Practices (GMP)** means the practices, which ensure that Finished Pharmaceutical Products are consistently produced and controlled according to quality standards appropriate to their intended use, and as required by applicable marketing authorizations.

**Health Products includes** (i) Finished Pharmaceutical Products;(ii) durable health products (including but not limited to bednets, laboratory equipment, radiology equipment and supportive products); and (iii) consumable/single-use health products (including but not limited to condoms, rapid and non-rapid diagnostic tests, insecticides, aerial sprays against mosquitoes, breast milk substitute and injection syringes).

**International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH)** is an initiative involving regulatory bodies and pharmaceutical industry experts that was established to make recommendations on ways to achieve greater harmonization in the interpretation and application of technical guidelines and requirements for product registration. ICH member countries are specified on its website: <http://www.ich.org> .

**Medicine** means an active pharmaceutical ingredient that is intended for human use.

**National Drug Regulatory Authority (NDRA)** means the official authority regulating Health Products in a country.

**NDRA-Recognized Laboratories** means Quality Control laboratories selected by NDRA according to their standards to conduct their Quality Control testing for Finished Pharmaceutical Products.

**Pharmaceutical Inspection Cooperation Scheme (PIC/S)** means the Swiss association of inspectorates which provides a forum for GMP training. The PIC/S is not subject to any international or domestic regulations. PIC/S member countries are specified on its website: [www.picscheme.org](http://www.picscheme.org) .

**Product Formulation** means an active pharmaceutical ingredient (or combination of ingredients), dosage form and strength.

**Quality Control** means all measures taken, including the setting of specification sampling, testing and analytical clearance, to ensure that starting material, intermediate, packaging material and Finished Pharmaceutical Products conform with established specifications for identity, strength, purity and other characteristics.

**Stringent Drug Regulatory Authority** means a regulatory authority which is (a) a member of the ICH (as specified on its website:); or (b) an ICH Observer, being the European Free Trade Association (EFTA), Health Canada and WHO (as may be updated from time to time); or (c) a regulatory authority associated with an ICH member through a legally binding mutual recognition agreement.

**WHO Prequalification Programme** means the programme managed by WHO which prequalifies (a) Medicines that are considered to be acceptable for procurement by the United Nations and specialized agencies; and (b) Quality Control laboratories for Medicines.

b. Health Product Management Assessment and PSM plan. Due to the complexity and significant risks of the procurement of Health Products, no Grant funds may be used to finance such procurement until:

- (1). the Global Fund has assessed the Principal Recipient's capability to manage such procurement; and
- (2). the Principal Recipient has submitted to the Global Fund, in form and substance satisfactory to the Global Fund, a plan for the procurement, use and supply management of Health Products that is consistent with this Article, (the "PSM Plan").

The Global Fund shall advise the Principal Recipient in writing whether it has approved the PSM Plan. The Principal Recipient shall ensure that the procurement and supply management of Health Product under the Program is carried out in accordance with the approved PSM Plan. The Principal Recipient must submit any proposed changes to the approved PSM Plan to the Global Fund for approval.

c. List of Medicines to be Procured. Grant funds may only be used to procure a Medicine that appears in the current Standard Treatment Guidelines (STG) or Essential Medicines Lists (EML) of the WHO, the Host Country government or an institution in the Host Country recognized by the Global Fund. The PSM Plan shall include the STG/EML that will apply to the Program.

The Principal Recipient shall submit a technical justification to the Global Fund if it intends to procure a Medicine that (i) was not specified in the grant proposal approved by the Global Fund; and (ii) is included in the relevant STG/EML of the Host Country government or an institution in the Host Country recognized by the Global Fund, but not included in the STG/EML of the WHO, or vice versa.

d. Procurement Responsibilities. In circumstances where the Global Fund has determined that the Principal Recipient possesses the requisite procurement capacity, the Principal Recipient shall be responsible for all procurement under the Agreement, and at its discretion, may use, or permit its Sub-recipients to use, contracted local, regional or international procurement agents to conduct procurements. If the Global Fund has determined that the Principal Recipient does not possess the requisite procurement capacity, the Principal Recipient shall use established regional or international procurement agents or other mechanisms acceptable to the Global Fund, but shall remain responsible for compliance of all procurement with the terms of this Agreement.

When a Sub-recipient carries out procurement of Health Products, the Principal Recipient shall ensure that such procurement is carried out in compliance with this Agreement.

In all cases, the Principal Recipient is encouraged to use, or cause Sub-recipients to use, capable regional and global procurement mechanisms wherever pooling of demand reduces prices for products and improves procurement efficiency.

e. Procurement Practices. The Principal Recipient shall ensure that the procurement of Finished Pharmaceutical Products under this Agreement adheres to the Interagency Operational Principles for Good Pharmaceutical Procurement. In cases where actual practices differ from these principles, the Principal Recipient shall demonstrate to the Global Fund that it has established a comparable system of competitive, transparent and accountable procurement

using a group of pre-qualified suppliers and the application of necessary quality assurance mechanisms.

In addition, Principal Recipients shall ensure that the procurement of Finished Pharmaceutical Products under this Agreement complies with the principles set forth in the Interagency Guidelines: A Model Quality Assurance System for Procurement Agencies (as amended from time to time).

f. Lowest Possible Price. The Principal Recipient shall use good procurement practices when procuring Health Products, including competitive purchasing from prequalified manufacturers and suppliers, as outlined in sub-section (e) above, to attain the lowest possible price of products that comply with the quality assurance standards specified in this Agreement. In determining what constitutes the “lowest possible price”, the Principal Recipient may take into account the unit price for the products, product registration, the delivery and insurance costs, and the delivery timeframe and method. With respect to durable products, the lowest possible price shall take into account the total cost of ownership, including the cost of reagents and other consumables as well as costs for annual maintenance.

g. Quality Standards for all Finished Pharmaceutical Products. Grant funds may only be used to procure Finished Pharmaceutical Products that have been authorized for use by the National Drug Regulatory Authority in the Host Country where the products will be used.

h. Additional Quality Standards for Antiretroviral, Antimalarial and/or Antituberculosis Finished Pharmaceutical Products. In addition to the quality standards specified in sub-section (g) above, Grant funds may only be used to procure antiretroviral, antimalarial and/or antituberculosis Finished Pharmaceutical Products that meet one of the following quality standards:

- (1). the product is prequalified under the WHO Prequalification Program or authorized for use by a Stringent Drug Regulatory Authority; or
- (2). the product has been recommended for use by the Expert Review Panel, as described in paragraph i of sub-section (i) below.

Such products may only be procured with Grant funds in accordance with the selection process specified in sub-section (i) below.

i. Selection Process for Procuring Antiretroviral, Antimalarial and/or Antituberculosis Finished Pharmaceutical Products.

- (1) If there are two or more Finished Pharmaceutical Products Available for the same Product Formulation that are either prequalified by the WHO or authorized for use by a Stringent Drug Regulatory Authority, the Principal Recipient may only use Grant funds to procure a Finished Pharmaceutical Product that meets either of those standards.
- (2). If a Principal Recipient determines that there is only one or no Finished Pharmaceutical Product Available that is prequalified by the WHO or authorized for use by a Stringent Drug Regulatory Authority and it wishes to use Grant funds to procure an alternate Finished Pharmaceutical Product, it must request confirmation from the Global Fund that the Principal Recipient’s determination is accurate and that the alternate Finished Pharmaceutical Product is currently



recommended for use by the Expert Review Panel. If the Global Fund provides this confirmation, the Principal Recipient may enter into a contract with a supplier for the procurement of the alternate Finished Pharmaceutical Product that has been recommended for use by the Expert Review Panel at any time until the end of the ERP Recommendation Period, but the duration of the contract shall not exceed 12 months. That is, the Principal Recipient may not place an order for that Finished Pharmaceutical Product under the contract more than 12 months after the contract is signed.

j. Quality Standards for Long-Lasting Insecticidal Mosquito Nets. Grant funds may only be used to procure long-lasting insecticidal mosquito nets that are recommended for use by the WHO Pesticide Evaluation Scheme.

k. Quality Standards for All Other Health Products. Grant funds may only be used to procure Health Products other than Finished Pharmaceutical Products or long-lasting insecticidal mosquito nets, if they are selected from lists of pre-qualified products, if any, and comply with quality standards applicable in the Host Country where such products will be use, if any.

l. Monitoring Supplier Performance. The Principal Recipient shall monitor the performance of suppliers with respect to the quality of the goods and services they supply and shall submit the information gathered to the Global Fund electronically for publication over the Internet through the Price and Quality Reporting mechanism referred to in sub-section (r).

m. Monitoring Product Quality. The Principal Recipient shall have systems in place to monitor the quality of Health Products financed under this Agreement that are acceptable to the Global Fund.

n. Quality Control Tests of Finished Pharmaceutical Products

(1). Subject to paragraph ii below, the Principal Recipient shall ensure that random samples of Finished Pharmaceutical Products financed under the Agreement are obtained at different points in the supply chain, from initial receipt of the products in the Host Country to the delivery of those products to patients. Such samples shall be sent to one of the following laboratories for Quality Control testing:

- (a) a laboratory prequalified by the WHO Prequalification Programme;
- (b) an NDRA or NDRA-Recognized Laboratory that meets one of the following criteria:
  - (i) Prequalified by WHO Prequalification Programme, or
  - (ii) Accredited in accordance with ISO17025; or
- (c) a laboratory contracted by the Global Fund.

Such Quality Control testing may be conducted in accordance with protocols and standard operating procedures prescribed by the Global Fund, as may be amended from time to time.

The Principal Recipient shall submit the results of the Quality Control tests to the Global Fund, which may be made available to the public.

- (2). If a Principal Recipient procures a Finished Pharmaceutical Product that has been recommended for use by the Expert Review Panel, the Global Fund will make the necessary arrangements for randomly selected samples of the Finished Pharmaceutical Product to be tested for Quality Control purposes, in accordance with advice provided by the Expert Review Panel, prior to the shipment and delivery of that product by the manufacturer to the Principal Recipient or other designated recipient. The Principal Recipient shall ensure that its contract with the manufacturer affords the Global Fund right to (i) obtain the manufacturer's specifications; (ii) remove samples of products and conduct random Quality Control testing while the products are within the possession of the manufacturer; and (iii) make the results of such testing available to the public. The cost of any such sampling and testing of the Finished Pharmaceutical Product shall be borne by the Global Fund.

o. Supply Chain and Inventory Management. With regard to the supply chain for Health Products financed under the Program, the Principal Recipient shall seek to ensure optimal reliability, efficiency and security.

The Principal Recipient shall comply with, and shall ensure that its Sub-Recipients comply with the WHO Guidelines for Good Storage Practices and Good Distribution Practices for Pharmaceutical Products. The Global Fund may approve deviations from such guidelines if the Principal Recipient can demonstrate to the Global Fund that comparable systems have been implemented to manage the storage and distribution of Finished Pharmaceutical Products procured with Grant funds.

p. Avoidance of Diversion. The Principal Recipient shall implement and ensure that Sub-recipients implement procedures that will avoid the diversion of Program financed health products from their intended and agreed-upon purpose. The procedures should include the establishment and maintenance of reliable inventory management, first-in first-out stock control systems, internal audit systems, and good governance structures to ensure the sound operation of these systems.

q. Adherence to Treatment Protocols, Drug Resistance and Adverse Effects. The Principal Recipient shall implement mechanisms to:

- (1)i. encourage patients to adhere to their prescribed treatments (which mechanisms shall include but not be limited to fixed-dose combinations, once-a-day formulations, blister packs, and peer education and support);
- (2). ensure prescribers' adherence to agreed treatment guidelines;
- (3). monitor and contain drug resistance; and
- (4) monitor adverse drug reactions according to existing international guidelines.

To help limit resistance to second-line tuberculosis Medicines and to be consistent with the policies of other international funding sources, all procurement of Medicines to treat multi-drug resistant tuberculosis financed under the Agreement must be conducted through the Green Light Committee of the Global Stop TB Partnership.

r. Price and Quality Reporting. Upon receipt in the country of Health Products purchased with Grant funds, the Principal Recipient shall promptly report to the Global Fund the prices it has paid for such Health Products and other information related to the quality of the Health Products, as specified in, and using the form of, the Price and Quality Reporting mechanism available on the website of the Global Fund.

#### **Article 19. UTILIZATION OF GOODS AND SERVICES**

All goods and services financed with Grant funds will, unless otherwise agreed in writing by the Global Fund, be devoted to the Program until the completion or termination of this Agreement, and thereafter unless the Principal Recipient and the Global Fund agree otherwise, any remaining property shall be transferred to the Global Fund. The Global Fund shall deal directly with the local authorities as necessary and appropriate regarding any such transfer.

#### **Article 20. AMENDMENT**

No modification of this Agreement shall be valid unless in writing and signed by an authorized representative of the Global Fund and the Principal Recipient.

#### **Article 21. TERMINATION; SUSPENSION**

a. Either the Global Fund or the Principal Recipient may terminate this Agreement in whole or in part upon giving the other party 60 days written notice. Either the Global Fund or the Principal Recipient may suspend this Agreement in whole or in part upon giving the other party seven days written notice. Any portion of this Agreement that is not terminated or suspended shall remain in full force and effect.

b. In the event that the Principal Recipient terminates this Agreement, it shall, if requested by the Global Fund, do its utmost to help to identify a suitable new entity to assume the responsibilities of implementing the Program.

c. Notwithstanding the termination of this Agreement, the Principal Recipient may use portions of the Grant that have already been disbursed to it to satisfy commitments and expenditures already incurred in the implementation of the Program before the date of termination. After the Principal Recipient has satisfied such commitments and liabilities, it will return all remaining Grant funds to the Global Fund or dispose of such funds as directed by the Global Fund.

d. In addition, upon full or partial termination or suspension of this Agreement, the Global Fund may, at the Global Fund's expense, direct that title to goods financed under the Grant, be transferred to the Global Fund if the goods are in a deliverable state.

#### **Article 22. NOVIATION; TRANSFER OF PRINCIPAL RECIPIENT RESPONSIBILITIES UNDER THIS AGREEMENT**

If at any time, either the Principal Recipient or the Global Fund concludes that the Principal Recipient is not able to perform the role of Principal Recipient and to carry out its responsibilities under this Agreement or if, for whatever reason, the Global Fund and the Principal Recipient wish to transfer some or all of the responsibilities of the Principal

Recipient to another entity that is able and willing to accept those responsibilities, then the Global Fund and the Principal Recipient may agree that the other entity (“New Principal Recipient”), may be substituted for the Principal Recipient in this Agreement. The substitution shall occur on such terms and conditions as the Global Fund and the New Principal Recipient agree, in consultation with the Country Coordinating Mechanism. The Principal Recipient hereby agrees to cooperate fully to make the transfer as smooth as possible.

**Article 23. NONWAIVER OF REMEDIES.**

No delay in exercising any right or remedy under this Agreement will be construed as a waiver of such right or remedy.

**Article 24. SUCCESSORS AND ASSIGNEES**

This Agreement shall be binding on the successors and assignees of the Principal Recipient and the Agreement shall be deemed to include the Principal Recipient’s successors and assignees. However, nothing in this Agreement shall permit any assignment without the prior written approval of the Global Fund.

**Article 25. LIMITS OF GLOBAL FUND LIABILITY**

a. The Global Fund shall be responsible only for performing the obligations specifically set forth in this Agreement. Except for those obligations, the Global Fund shall have no liability to the Country Coordinating Mechanism, the Principal Recipient, Sub-recipients or any other person or entity as a result of this Agreement or the implementation of the Program.

b. The Principal Recipient undertakes the Program on its own behalf and not on behalf of the Global Fund. This Agreement and the Grant shall in no way be construed as creating the relationship of principal and agent, of partnership in law or of joint venture as between the Global Fund and the Principal Recipient or any other person involved in the Program. The Global Fund assumes no liability for any loss or damage to any person or property arising from the Program.

**Article 26. ARBITRATION**

a. Any dispute between the Global Fund and the Principal Recipient arising out of or relating to this Agreement that is not settled amicably shall be submitted to arbitration at the request of either Party. The arbitration shall be conducted in accordance with UNCITRAL Arbitration Rules as at present in force. The Global Fund and the Principal Recipient agree to be bound by the arbitration award rendered in accordance with such arbitration, as the final adjudication of any such dispute, controversy, or claim.

b. For any dispute for which the amount at issue is 100,000 United States dollars or less, there shall be one arbitrator.

c. For any dispute for which the amount at issue is greater than 100,000 United States dollars, there shall be three arbitrators appointed as follows: The Global Fund and the

Principal Recipient shall each appoint one arbitrator, and the two arbitrators so appointed shall jointly appoint a third who shall be the chairperson.

**Article 27. CONFLICTS OF INTEREST; ANTI-CORRUPTION**

a. The Parties agree that it is important to take all necessary precautions to avoid conflicts of interest and corrupt practices. To this end, the Principal Recipient shall maintain standards of conduct that govern the performance of its staff, including the prohibition of conflicts of interest and corrupt practices in connection with the award and administration of contracts, grants, or other benefits, as set forth in the Staff Regulations and Rules of the United Nations, the UNDP Financial Regulations and Rules, and the UNDP Procurement Manual.

b. No person affiliated with the Principal Recipient (staff, individual contractors, counterpart government officials) shall participate in the selection, award or administration of a contract, grant or other benefit or transaction funded by the Grant, in which the person, members of the person's immediate family or his or her business partners, or organizations controlled by or substantially involving such person, has or have a financial interest. No person affiliated with the Principal Recipient (staff, individual contractors, counterpart government officials) shall participate in such transactions involving organizations or entities with which or whom that person is negotiating or has any arrangement concerning prospective employment. Persons affiliated with the Principal Recipient (staff, individual contractors, counterpart government officials) shall not solicit gratuities, favors or gifts from contractors or potential contractors.

c. If the Principal Recipient has knowledge or becomes aware of any actual, apparent or potential conflict between the financial interests of any person affiliated with the Principal Recipient, the Country Coordinating Mechanism, the LFA, or the Global Fund and that person's duties with respect to the implementation of the Program, the Principal Recipient shall immediately disclose the actual, apparent or potential conflict of interest directly to the Global Fund.

d. The Global Fund and the Principal Recipient shall neither offer a third person nor seek, accept or be promised directly or indirectly for themselves or for another person or entity any gift or benefit that would or could be construed as an illegal or corrupt practice

**Article 28. PRIVILEGES AND IMMUNITIES**

Nothing in or related to this Agreement may be construed as a waiver, express or implied of:

a. the privileges and immunities of the Principal Recipient pursuant to the Convention on the Privileges and Immunities of the Specialized Agencies, approved by the General Assembly of the United Nations on November 21, 1947 or otherwise under any international or national law, convention or agreement; or

b. the privileges and immunities accorded to the Global Fund under (i) international law including international customary law, any international conventions or agreements, (ii) under any national laws including but not limited to the to the United States of America's International Organizations Immunities Act (22 United States Code 288), or

(iii) under the Headquarters Agreement between the Global Fund and the Swiss Federal Council dated 13 December 2004.